➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
Colorcon
McKesson
Harvard Business School

Last Updated: September 25, 2021

DrugPatentWatch Database Preview

MAVYRET Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Mavyret patents expire, and what generic alternatives are available?

Mavyret is a drug marketed by Abbvie Inc and is included in two NDAs. There are seven patents protecting this drug.

This drug has four hundred and fifty-four patent family members in forty-four countries.

The generic ingredient in MAVYRET is glecaprevir; pibrentasvir. One supplier is listed for this compound. Additional details are available on the glecaprevir; pibrentasvir profile page.

DrugPatentWatch® Generic Entry Outlook for Mavyret

Mavyret was eligible for patent challenges on August 3, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 5, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for MAVYRET
International Patents:454
US Patents:7
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
Clinical Trials: 10
Drug Prices: Drug price information for MAVYRET
What excipients (inactive ingredients) are in MAVYRET?MAVYRET excipients list
DailyMed Link:MAVYRET at DailyMed
Drug patent expirations by year for MAVYRET
Drug Prices for MAVYRET

See drug prices for MAVYRET

DrugPatentWatch® Estimated Generic Entry Opportunity Date for MAVYRET
Generic Entry Dates for MAVYRET*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL
Generic Entry Dates for MAVYRET*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
PELLETS;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MAVYRET

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AbbViePhase 3
NYU Langone HealthEarly Phase 1
Mayo ClinicPhase 4

See all MAVYRET clinical trials

US Patents and Regulatory Information for MAVYRET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc MAVYRET glecaprevir; pibrentasvir PELLETS;ORAL 215110-001 Jun 10, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Abbvie Inc MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394-001 Aug 3, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Abbvie Inc MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394-001 Aug 3, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Abbvie Inc MAVYRET glecaprevir; pibrentasvir PELLETS;ORAL 215110-001 Jun 10, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Abbvie Inc MAVYRET glecaprevir; pibrentasvir PELLETS;ORAL 215110-001 Jun 10, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Abbvie Inc MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394-001 Aug 3, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for MAVYRET

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2692346 PA2017033,C2692346 Lithuania ⤷  Try it Free PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2692346 2017/046 Ireland ⤷  Try it Free PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2368890 300731 Netherlands ⤷  Try it Free PRODUCT NAME: OMBITASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119
2618831 17C1039 France ⤷  Try it Free PRODUCT NAME: GLECAPREVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN ESTER DE CELUI-CI; REGISTRATION NO/DATE: EU/1/17/1213 20170728
2368890 15C0016 France ⤷  Try it Free PRODUCT NAME: OMBITASVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119
2618831 LUC00037 Luxembourg ⤷  Try it Free PRODUCT NAME: GLECAPREVIR OU UN SEL OU ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1213 20170728
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
Colorcon
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.